Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Subscribe To Our Newsletter & Stay Updated
